Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
Talha Munir(St James's University Hospital), Jennifer A. Woyach(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Sandra Dai(AbbVie (United States)), Steven Coutré(Georgetown University), Jennifer R. Brown(Dana-Farber Cancer Institute), Constantine S. Tam(The Alfred Hospital), Thomas J. Kipps(University of California San Diego), Marco Montillo(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Paul M. Barr(University of Rochester Medical Center), Carol Moreno(Hospital de Sant Pau), Jan A. Burger(The University of Texas MD Anderson Cancer Center), Jacqueline C. Barrientos(Mount Sinai Medical Center), Nishitha Reddy(Vanderbilt University), Stephen P. Mulligan(Royal North Shore Hospital), James P. Dean(AbbVie (United States)), Anita Szőke(AbbVie (United States)), John C. Byrd(University of Cincinnati), Ulrich Jaeger(Medical University of Vienna), Susan O’Brien(University of California, Irvine)
Cited by 472
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|9.9k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k